Estudio aleatorizado controlado con placebo de OSI-774 (erlotinib HCl, Tarceva[TM]) en pacientes con cáncer de pulmón de células no pequeñas en estadio IIIB/IV incurable que no respondieron al tratamiento estándar para la enfermedad avanzada o metastásica

Criterios de inclusión

• Clinical diagnosis of stage IIIB or IV non-small cell lung cancer.
• Must have evidence of disease (clinical or radiological).
• Have failed 1 but no more than 2 prior chemotherapy regimens, have recovered from any side effects and have not had any chemotherapy for at least 21 days.
• If the patient has had surgery, the surgery was at least 2 weeks ago.
• Patients whose cancer has spread to their brain or central nervous system are eligible, providing that they have been on stable dose of steroids for at least 4 weeks and are free of symptoms.
• If the patient received radiation therapy, treatment was at least 4 weeks ago.